Legal & General Group PLC Arcus Biosciences, Inc. Transaction History

Legal & General Group PLC

  • $440 Billion
  • Q2 2024

A detailed history of Legal & General Group PLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 152,901 shares of RCUS stock, worth $2.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
152,901
Previous 150,252 1.76%
Holding current value
$2.36 Million
Previous $2.84 Million 17.91%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$14.59 - $18.48 $38,648 - $48,953
2,649 Added 1.76%
152,901 $2.33 Million
Q1 2024

May 14, 2024
BUY
$14.83 - $20.18 $19,605 - $26,677
1,322 Added 0.89%
150,252 $2.84 Million
Q4 2023

Feb 15, 2024
SELL
$13.43 - $19.63 $16,988 - $24,831
-1,265 Reduced 0.84%
148,930 $2.84 Million
Q3 2023

Nov 14, 2023
BUY
$17.62 - $23.54 $90,566 - $120,995
5,140 Added 3.54%
150,195 $2.7 Million
Q2 2023

Aug 14, 2023
SELL
$16.97 - $22.03 $64,231 - $83,383
-3,785 Reduced 2.54%
145,055 $2.95 Million
Q1 2023

May 15, 2023
SELL
$15.96 - $23.15 $27,690 - $40,165
-1,735 Reduced 1.15%
148,840 $2.71 Million
Q4 2022

Feb 14, 2023
BUY
$19.7 - $35.71 $39,872 - $72,277
2,024 Added 1.36%
150,575 $3.11 Million
Q3 2022

Nov 14, 2022
BUY
$23.23 - $30.07 $263,312 - $340,843
11,335 Added 8.26%
148,551 $3.89 Million
Q2 2022

Aug 22, 2022
BUY
$17.23 - $37.73 $1.72 Million - $3.78 Million
100,107 Added 269.76%
137,216 $3.48 Million
Q1 2022

May 16, 2022
BUY
$28.92 - $41.83 $556,044 - $804,265
19,227 Added 107.52%
37,109 $1.17 Million
Q4 2021

Feb 14, 2022
SELL
$31.38 - $48.47 $15,125 - $23,362
-482 Reduced 2.62%
17,882 $723,000
Q3 2021

Nov 15, 2021
BUY
$26.93 - $37.68 $217,998 - $305,019
8,095 Added 78.83%
18,364 $640,000
Q2 2021

Aug 12, 2021
SELL
$22.75 - $35.77 $28,141 - $44,247
-1,237 Reduced 10.75%
10,269 $281,000
Q1 2021

May 17, 2021
BUY
$26.16 - $41.39 $11,641 - $18,418
445 Added 4.02%
11,506 $323,000
Q4 2020

Feb 12, 2021
SELL
$17.0 - $32.36 $1,360 - $2,588
-80 Reduced 0.72%
11,061 $287,000
Q3 2020

Nov 13, 2020
SELL
$17.14 - $25.47 $5,484 - $8,150
-320 Reduced 2.79%
11,141 $191,000
Q2 2020

Aug 14, 2020
BUY
$13.97 - $36.56 $90,469 - $236,762
6,476 Added 129.91%
11,461 $284,000
Q1 2020

May 14, 2020
SELL
$8.78 - $19.28 $14,794 - $32,486
-1,685 Reduced 25.26%
4,985 $69,000
Q3 2019

Nov 13, 2019
BUY
$6.44 - $10.18 $5,486 - $8,673
852 Added 14.64%
6,670 $61,000
Q4 2018

Feb 15, 2019
BUY
$9.74 - $14.5 $42,894 - $63,858
4,404 Added 311.46%
5,818 $62,000
Q3 2018

Nov 20, 2018
BUY
$10.88 - $14.95 $7,082 - $9,732
651 Added 85.32%
1,414 $20,000
Q2 2018

Aug 10, 2018
BUY
$12.24 - $17.05 $9,339 - $13,009
763 New
763 $9,000

Others Institutions Holding RCUS

# of Institutions
207
Shares Held
49M
Call Options Held
173K
Put Options Held
151K
View Full List

About Arcus Biosciences, Inc.

RCUS Quotes by TradingView
  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.11B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email